Surgical Oncology | Montefiore Einstein

Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein.  Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
Dr. Stiles is also heavily involved with translational and basic research.  Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.   In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation. 
Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.  Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.  ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.
Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.

Research Areas

Basic/Translational:
Tumor microenvironment,
Mono-ADP-ribosylation,
ART1
Predictors of response to immunotherapy.

Clinical:
Lung cancer,
Lung cancer screening,
Neoadjuvant therapy,

Specialties

Cancer

Expert Tags

Lung Cancer

Surgical Oncology

Areas of Expertise

Lung cancer detection & treatment

Patient advocacy

Expert Summary

Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.

Research Profile

https://einsteinmed.edu/faculty/16884/Brendon-Stiles

Clinical Profile

https://montefioreeinstein.org/profiles/1013176387/brendon-m-stiles

CHAM Provider

Off

Professional Title

M.D.

Clinical Focus

Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. <quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.  In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

https://einstein.pure.elsevier.com/en/persons/41add037-1c2e-4849-8877-ee4de2239…

Selected Publications

Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.  Science Translational Medicine. 2022 Mar 16;14(636):eabe8195.  <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis." Nature Reviews Cancer 19.1 (2019): 9-31.
Yao, Zhan, et al. "TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer." Proceedings of the National Academy of Sciences 107.35 (2010): 15535-15540.
Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition." Cancer research 72.6 (2012): 1384-1394.
Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial." The Lancet Oncology 22.6 (2021): 824-835.
Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells." JOURNAL FOR IMMUNOTHERAPY OF CANCER. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.
Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms." Journal of Thoracic Oncology 11.2 (2016): S44.
https://scholar.google.com/citations?user=fR4OkgkAAAAJ&hl=en&oi…;

EMR ID

82842

Biography

Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.“The recruitment of Dr. Stiles elevates the treatment of lung cancer to a historic level,” said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein. “Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.”After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.  He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.  In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.  Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.

Is Open Scheduling

Off